The efficacy and safety of the biosimilar product (Inflectra®) compared to the reference drug (Remicade®) in rescue therapy in adult patients with ulcerative colitis

The efficacy and safety of the biosimilar product (Inflectra®) compared to the reference drug (Remicade®) in rescue therapy in adult patients with ulcerative colitis

Introduction : The biosimilar product Inflectra® has been approved by the European Medicine Agency (EMA) for the same indications as its reference drug, infliximab, based on studies in patients with rheumatic diseases. Thus far, there have not been enough data regarding its efficacy and safety in ul...

Full description

Saved in:
Bibliographic Details
Main Authors: Magdalena Kaniewska, Andrzej Moniuszko, Grażyna Rydzewska
Format: Article
Language:English
Published: Termedia Publishing House 2017-09-01
Series:Gastroenterology Review
Subjects:
inflammatory bowel disease
ulcerative colitis
biological treatment
biosimilar drug
endoscopic remission
Online Access:https://www.termedia.pl/The-efficacy-and-safety-of-the-biosimilar-product-Inflectra-compared-to-the-reference-drug-Remicade-in-rescue-therapy-in-adult-patients-with-ulcerative-colitis,41,30724,1,1.html
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.termedia.pl/The-efficacy-and-safety-of-the-biosimilar-product-Inflectra-compared-to-the-reference-drug-Remicade-in-rescue-therapy-in-adult-patients-with-ulcerative-colitis,41,30724,1,1.html

Similar Items